{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:01:42Z","timestamp":1768399302392,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Medizinische Leitlinien dienen als systematische Entscheidungshilfen, um eine evidenzbasierte und angemessene \u00e4rztliche Vorgehensweise bei bestimmten Krankheitsbildern zu gew\u00e4hrleisten. In Deutschland werden dermatologische Leitlinien unter der Federf\u00fchrung der Deutschen Dermatologischen Gesellschaft (DDG) und des Berufsverbandes der Deutschen Dermatologen (BVDD) entsprechend den methodischen Vorgaben der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) entwickelt. Im Zeitraum 2023 bis 2024 wurden verschiedene Leitlinien mit Bezug zur Dermatologie \u00fcberarbeitet oder neu herausgegeben. Dazu geh\u00f6ren unter anderem die Leitlinie zur Diagnostik und Therapie der epidermalen Nekrolyse (Stevens-Johnson-Syndrom und toxische epidermale Nekrolyse), der atopischen Dermatitis, der Hidradenitis suppurativa\/Acne inversa, der kutanen Lyme-Borreliose, der prim\u00e4ren Hyperhidrose, der zirkumskripten Sklerodermie, zum Screening auf anale Dysplasien und Analkarzinome bei HIV(humanes Immundefizienzvirus)-Infizierten, zu Aphthen und aphth\u00f6sen L\u00e4sionen der Mund- und Rachenschleimhaut, zur allergologischen Diagnostik von \u00dcberempfindlichkeitsreaktionen auf Arzneimittel. Dar\u00fcber hinaus wurden Aktualisierungen zu den Themen Basalzellkarzinom der Haut, analer Pruritus, Analekzem, aktinische Keratose und Plattenepithelkarzinom der Haut, Bienen- und Wespengiftallergie sowie Handekzem ver\u00f6ffentlicht. Diese \u00dcbersicht fasst die wichtigsten Empfehlungen und Neuerungen der aktuellen dermatologischen Leitlinien zusammen.<\/jats:p>","DOI":"10.1007\/s00105-025-05601-1","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:23:09Z","timestamp":1760973789000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle dermatologische Leitlinien in Deutschland: eine Auswahl klinisch relevanter Empfehlungen","Current dermatology guidelines in Germany: a\u00a0selection of clinically relevant recommendations"],"prefix":"10.1007","volume":"77","author":[{"given":"Marie Anne","family":"Pradeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kinberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chromy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Jackowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Ru\u00ebff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"5601_CR1","unstructured":"AKOPOM, DGMKG, DGZMK (2021) \u201eDiagnostik und Therapieoptionen von Aphthen und aphthoiden L\u00e4sionen der Mund- und Rachenschleimhaut\u201c, Langfassung 2.0 (AWMF-Registriernummer: 007-101). https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/007-101.html. Zugegriffen: 6. Mai 2025"},{"key":"5601_CR2","first-page":"1025","volume":"23","author":"D Chromy","year":"2025","unstructured":"Chromy\u00a0D, Aigner\u00a0F, Becker\u00a0JC et al. (2025) German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV. J Dtsch Dermatol Ges 23:1025\u20131040","journal-title":"J Dtsch Dermatol Ges"},{"key":"#cr-split#-5601_CR3.1","doi-asserted-by":"crossref","unstructured":"Heppt\u00a0MV, Leiter\u00a0U, Steeb\u00a0T et al. (2023) S3-Leitlinie \"Aktinische Keratose und Plattenepithelkarzinom der Haut\" - Update 2023, Teil\u00a01: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen","DOI":"10.1111\/ddg.15231_g"},{"key":"#cr-split#-5601_CR3.2","doi-asserted-by":"crossref","unstructured":"S3 guideline \"actinic keratosis and cutaneous squamous cell carcinoma\"-update 2023, part\u00a01: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care. J Dtsch Dermatol Ges 21:1249-1262","DOI":"10.1111\/ddg.15231"},{"key":"5601_CR4","unstructured":"(2024) S1-Leitlinie \u201eAnaler Pruritus\u201c (AWMF-Registernr. 013-063). https:\/\/register.awmf.org\/assets\/guidelines\/013-063l_S1_Analer-Pruritis_2024-11.pdf. Zugegriffen: 6. Mai 2025"},{"key":"5601_CR5","unstructured":"(2023) S1-Leitlinie \u201eDefinition und Therapie der prim\u00e4ren Hyperhidrose\u201c (AWMF-Registernr. 013-059). https:\/\/register.awmf.org\/assets\/guidelines\/013-059l_S1_Definition-Therapie-primaeren-Hyperhidrose_2023-07.pdf. Zugegriffen: 6. Mai 2025"},{"key":"5601_CR6","unstructured":"(2024) S1-Leitlinie \u201eDiagnostik und Therapie des Analekzems\u201c (AWMF-Registernr. 013-007). https:\/\/register.awmf.org\/assets\/guidelines\/013-007l_S1_Diagnostik-Therapie_Anakekzem_2024-11.pdf. Zugegriffen: 6. Mai 2025"},{"key":"5601_CR7","first-page":"605","volume":"22","author":"A Kreuter","year":"2024","unstructured":"Kreuter\u00a0A, Moinzadeh\u00a0P, Kinberger\u00a0M et al. (2024) S2k guideline: Diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 22:605\u2013620","journal-title":"J Dtsch Dermatol Ges"},{"key":"5601_CR8","unstructured":"(2023) S2k-Leitlinie \u201eKutane Lyme Borreliose\u201c (AWMF-Registernr. 013-044). https:\/\/derma.de\/fileadmin\/derma\/1_derma.de_WebRoot\/Leitlinien\/013-044l_S2k_Kutane_Lyme_Borreliose_2024-06.pdf. Zugegriffen: 6. Mai 2025"},{"issue":"33","key":"5601_CR9","first-page":"2154","volume":"94","author":"RE Bloch","year":"1997","unstructured":"Bloch\u00a0RE, Lauterbach\u00a0K, Oesingmann\u00a0U, Rienhoff\u00a0O, Schirmer\u00a0HD, Schwartz\u00a0FW (1997) Beurteilungskriterien f\u00fcr Leitlinien in der medizinischen Versorgung-Beschl\u00fcsse der Vorst\u00e4nde von Bundes\u00e4rztekammer und Kassen\u00e4rztlicher Bundesvereinigung. Dtsch \u00c4rztebl 94(33):2154\u20132155","journal-title":"Dtsch \u00c4rztebl"},{"key":"5601_CR10","doi-asserted-by":"crossref","unstructured":"Brockow K, Wurpts G, Trautmann A et\u00a0al. (2023) Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Dermatological Society (DDG), the Association of German Allergologists (\u00c4DA), the German Society for Pediatric Allergology (GPA), the German Contact Dermatitis Research Group (DKG), the German Society for Pneumology (DGP), the German Society of Otorhinolaryngology, Head and Neck Surgery, the Austrian Society of Allergology and Immunology (\u00d6GAI), the Austrian Society of Dermatology and Venereology (\u00d6GDV), the German Academy of Allergology and Environmental Medicine (DAAU), and the German Documentation Center for Severe Skin Reactions (dZh). Allergol Select 7:122\u2013139","DOI":"10.5414\/ALX02422E"},{"key":"5601_CR11","first-page":"1448","volume":"22","author":"R Heuer","year":"2024","unstructured":"Heuer\u00a0R, Paulmann\u00a0M, Annecke\u00a0T et\u00a0al (2024) S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)\u2014Part\u00a01: Diagnosis, initial management, and immunomodulating systemic therapy. J\u00a0Dtsch Dermatol Ges 22:1448\u20131466","journal-title":"J Dtsch Dermatol Ges"},{"key":"5601_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12312-024-01340-x","volume":"39","author":"N Laubach","year":"2024","unstructured":"Laubach\u00a0N, Grabbe\u00a0S, Lang\u00a0BM (2024) S2k-Leitlinie Basalzellkarzinom der Haut. Forum 39:250\u2013252","journal-title":"Forum"},{"key":"5601_CR13","first-page":"1576","volume":"22","author":"M Paulmann","year":"2024","unstructured":"Paulmann\u00a0M, Heuer\u00a0R, Annecke\u00a0T et\u00a0al (2024) S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)\u2014Part\u00a02: Supportive therapy of EN in the acute and post-acute stages. J\u00a0Dtsch Dermatol Ges 22:1576\u20131593","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"5601_CR14","first-page":"16","volume":"72","author":"F Ru\u00ebff","year":"2024","unstructured":"Ru\u00ebff\u00a0F, Bauer\u00a0A, Becker\u00a0S, Brehler\u00a0R, Brockow\u00a0K, Chaker\u00a0AM, Jakob\u00a0T (2024) Diagnose und Therapie der Bienen- und Wespengiftallergie. DB 72(1):16","journal-title":"DB"},{"key":"5601_CR15","first-page":"307","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel\u00a0T, Heratizadeh\u00a0A, Aberer\u00a0W et\u00a0al (2024) S3 guideline Atopic dermatitis: Part\u00a02\u2014Systemic treatment. J\u00a0Dtsch Dermatol Ges 22:307\u2013320","journal-title":"J Dtsch Dermatol Ges"},{"key":"5601_CR16","first-page":"137","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel\u00a0T, Heratizadeh\u00a0A, Aberer\u00a0W et\u00a0al (2024) S3 Guideline Atopic dermatitis: Part\u00a01\u2014General aspects, topical and non-drug therapies, special patient groups. J\u00a0Dtsch Dermatol Ges 22:137\u2013153","journal-title":"J Dtsch Dermatol Ges"},{"key":"5601_CR17","first-page":"868","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis\u00a0CC, Bechara\u00a0FG, Fritz\u00a0K et\u00a0al (2024) S2k guideline for the treatment of hidradenitis suppurativa \/ acne inversa\u2014Short version. J\u00a0Dtsch Dermatol Ges 22:868\u2013889","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-025-05601-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:52:33Z","timestamp":1768380753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-025-05601-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5601"],"URL":"https:\/\/doi.org\/10.1007\/s00105-025-05601-1","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.A.\u00a0Pradeau erhielt die Finanzierung einer Kongressteilnahme mit Reisekosten\u00fcbernahme von Pierre Fabre und Galderma. C.C.\u00a0Zouboulis erhielt Honorare als Berater f\u00fcr Almirall, Biogen, Boehringer Ingelheim, CLS Behring, Eli Lilly and Company, Est\u00e9e Lauder, Idorsia, Incyte, Leo, L&#39; Or\u00e9al, MSD, NAOS-BIODERMA, Novartis, PPM, Sanofi, SciRhom, Takeda, UCB und Zura Bio sowie Vortragshonorare von Almirall, Amgen, NAOS-BIODERMA, Biogen, BMS, L&#39; Or\u00e9al, Novartis, Pfizer und UCB. Seine Abteilungen haben Zusch\u00fcsse aus seiner Teilnahme an klinischen und experimentellen Studien f\u00fcr AstraZeneca, Boehringer Ingelheim, BMS, die Medizinische Hochschule Brandenburg Theodor Fontane, European Academy of Dermatology and Venereology (EADV), die Europ\u00e4ische Union, das Bundesministerium f\u00fcr Bildung und Forschung, GSK, Incyte, InflaRx, MSD, Novartis, Relaxera, Sanofi und UCB erhalten. Er ist Pr\u00e4sident der European Hidradenitis Suppurativa Foundation (EHSF) e.\u202fV., Pr\u00e4sident des Deutschen Registers Morbus Adamantiades-Beh\u00e7et e.\u202fV., Vorstandsmitglied der International Society for Beh\u00e7et\u2019s Disease, Koordinator der ALLOCATE Skin Gruppe des European Reference Network for Rare and Complex Skin Diseases (ERN Skin) und Vorsitzender der Acne, Rosacea and Hidradenitis Suppurativa (ARHS) Task Force Gruppe der EADV. Er ist Herausgeber der EADV News und Miturheber der IHS4 und IHS4-55 im Namen der EHSF e.\u202fV. D.\u00a0Chromy: Beratungst\u00e4tig f\u00fcr Gilead Science und GSK\/ViiV Healthcare, Reiseunterst\u00fctzung von Gilead Science, GSK\/ViiV Healthcare, Eli Lilly und MSD. J.\u00a0Jackowski: Vortragst\u00e4tigkeit: AKOPOM, AGOKi, Z\u00c4K Nordrhein, Z\u00c4K WL; Beratert\u00e4tigkeit: NAMSE (Mandatstr\u00e4ger der BZ\u00c4K im Nationalen Aktionsb\u00fcndnis f\u00fcr Menschen mit seltenen Erkrankungen), OGI (Vorsitzender des wissenschaftlichen Beirates Orale Gesundheit inklusiv). K.\u00a0Brockow erhielt Honorare f\u00fcr Vortr\u00e4ge\/Beratung (advisory boards) von Novartis, Phadia (Thermo Fisher), BioMarin Pharmaceutical Inc., UpToDate Inc., AstraZeneca, Blueprint, ALK, Celltex, Bencard und Materialkosten f\u00fcr Forschung von Thermo Fisher und Macro Array Diagnostics. F.\u00a0Ru\u00ebff erhielt Honorare f\u00fcr Vortr\u00e4ge\/Beratungen von Arzneimittelherstellern: ALK-Abell\u00f3 Arzneimittel GmbH, Allergopharma GmbH, Blueprint Medicines (Germany) GmbH, Boehringer Ingelheim, LEO Pharma, Mylan, Novartis, Thermo Fisher, Diagnostics Austria GmbH und UCB Pharma GmbH. Sie erhielt Honorare f\u00fcr Vortr\u00e4ge\/Beratungen von wissenschaftlichen Fachgesellschaften oder gewerblichen Veranstaltern: Agentur Herzberg, b4c Solutions GmbH, Charit\u00e9 Universit\u00e4tsmedizin CSACI, DGAKI, DGP, EAACI, ECM GmbH, Exafield GmbH. FomF GmbH, GAZLEN, INTERPLAN Fortbildungswoche GmbH, m:con\u00a0\u2013 mannheim:congress GmbH, RG Gesellschaft f\u00fcr Information und Organisation mIHM Results GmbH, wikonect GmbH. In den letzten 3\u00a0Jahren wurden an das Klinikum der Universit\u00e4t M\u00fcnchen Zahlungen f\u00fcr klinische Pr\u00fcfungen unter ihrer Leitung get\u00e4tigt: Arctic Bioscience AS, ArgenxBV, Aristea Therapeutics Inc., Blueprint Medicines Corporation, Derma2Go, Boehringer Ingelheim, Bristol Myers Squibb, Celldex, Galderma, Heidelberg\u00a0ImunoTherapeutics GmbH, Immunotherapeutics AG, InflaRx GmbH, LEO Pharma, Lilly, Moonlake, Nektar Therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Sanofi Aventis, UCB und Union Therapeutics. M.\u00a0Kinberger und A.\u00a0Nast geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}